Scholarly Works - Book sections
Book section
·
January 1, 2023
Parenteral anticoagulant therapies include heparin and related compounds, as well as the direct thrombin inhibitors argatroban and bivalirudin. Commonly used fibrinolytic therapies include alteplase, reteplase, and tenecteplase. Oral anticoagulant therapie ...
Full text
Cite
Book section
·
January 1, 2022
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by venous and/or arterial thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid antibodies. These autoantibodies bind to β2-glycoprotein I and other phosphol ...
Full text
Cite
Book section
·
January 1, 2021
Cytopenias are frequently encountered in patients with systemic lupus erythematosus (SLE), and leukopenia (white blood cell count <4000/mm3), thrombocytopenia (platelet count <100, 000/mm3), and autoimmune hemolytic anemia (defined by ...
Full text
Cite
Book section
·
January 1, 2021
Antithrombotic therapy, which includes therapies targeting platelets as well as the coagulation system, is used to prevent and treat thromboembolic disease. Antiplatelet agents are most frequently used to prevent stroke and myocardial infarction, but they ...
Full text
Cite
Book section
·
January 1, 2019
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by venous and/or arterial thromboembolic events, recurrent pregnancy morbidity, and the persistent presence of antiphospholipid antibodies. These autoantibodies bind to β2-glycoprotein ...
Full text
Cite
Book section
·
January 1, 2017
Available evidence supports an inherited risk for the occurrence of antiphospholipid antibodies (aPL), with or without the clinical manifestations associated with antiphospholipid syndrome (APS). Immediate relatives of individuals with APS, whether primary ...
Full text
Cite
Book section
·
January 1, 2017
A challenge in antiphospholipid syndrome (APS) is to translate targeted therapies from animal and in vitro models to clinical trials. The 15th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Treatment Trends summarized new develop ...
Full text
Cite
Book section
·
January 1, 2017
Catastrophic antiphospholipid syndrome (CAPS) is a systemic disorder, resulting in both thrombotic and non-thrombotic events. Thrombosis manifests mainly as thrombotic microangiopathy (TMA), although large-vessel thrombosis occurs in up to one third of pat ...
Full text
Cite
Book section
·
January 1, 2016
Patients with renal diseases have their own particular complications of hemostasis and thrombosis. Bleeding and platelet dysfunction is a common complication of chronic kidney disease and uremia. Similarly, coagulation activation and risk of thrombosis is ...
Full text
Cite
Book section
·
January 1, 2014
Anticoagulation is a fundamental of management in venous disease. This chapter discusses anticoagulant therapy and a variety of agents. The current treatment for a new venous thromboembolic event in a patient is anticoagulant therapy, beginning with either ...
Full text
Cite
Book section
·
March 1, 2013
Molecular testing is frequently used in conjunction with other laboratory analyses in the evaluation of patients with hemorrhagic as well as thrombotic disorders. The most common thrombophilic defects, factor V Leiden and the prothrombin G20210A mutation, ...
Full text
Cite
Book section
·
January 1, 2012
An inherited risk for the occurrence of antiphospholipid antibodies (aPLs), with or without the clinical manifestations associated with antiphospholipid syndrome (APS), is supported by multiple lines of evidence. Family members of patients with APS, whethe ...
Full text
Cite
